U.S. study of intravenous mistletoe extract to treat advanced cancer



U.S. study of intravenous mistletoe extract to treat advanced cancer

Researchers completed what is believed to be the first phase I trial of intravenous Helixor M in the U.S. aimed at determining dosing for subsequent clinical trials and to evaluate safety.

Materials provided by Johns Hopkins Medicine. Note: Content may be edited for style and length.




Source link aaaaa

Related posts

18th March 2023

New combination of drugs works together to reduce lung tumors in mice

Read more
17th March 2023

Study offers a potential strategy to improve T cell therapy in solid tumors

Read more
17th March 2023

Researchers chart a course for understanding, preventing, and treating young-onset colorectal cancer

Read more